Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stevia venture

This article was originally published in The Tan Sheet

Executive Summary

A joint venture by stevia producer GLG Life Tech and fitness product firm Weider Global Nutrition aims to bring dietary and tabletop supplements made with stevia leaf extracts into international markets, GLG announces Sept. 9. GLG Weider Sweet Naturals Corp. will leverage the stevia extraction expertise of Vancouver, British Columbia-based GLG, and the sales and distribution capacities of Salt Lake City-based Weider to "provide consumers a great tasting, natural and zero-calorie alternative to artificial sweeteners and calorie-laden sugar," says GLG President Brian Palmieri. Though multiple U.S. companies are either marketing or developing stevia-based sweeteners, FDA has not declared the substance safe as a food additive and consumer groups have questioned stevia safety data (1"The Tan Sheet" Sept. 1, 2008, p. 16)

You may also be interested in...

Stevia Safety Certifications Lacking FDA OK Called Into Question

The Center for Science in the Public Interest maintains FDA's process for certifying a substance as generally recognized as safe is insufficient and has left the door open for the marketing of potentially unsafe sweeteners made from the stevia leaf

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts